Mayaro virus: novel synthetic DNA vaccine provides immunity in preclinical trials


Scientists from the Wistar Institute (PA, USA) have successfully induced effective immunity against the Mayaro virus (MAYV); an emerging virus with epidemic potential. The findings, published in PLoS Neglected Tropical Diseases, detail the team’s use of a novel synthetic DNA vaccine to target a viral envelope (E) protein found in MAYV major circulating strains.

MAYV presence has been well-documented in and around South America for over 50 years but currently, there are no therapeutics for prevention or treatment available. Infections present with symptoms like those seen with chikungunya infections.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment